In the past decade, a new character of the patent theatre has made inroads into the case law of some EU Member States, “imported” from the so-called “EPO case law”. Its name is “plausibility”. The origin of the plausibility concept can be traced to Decision T 939/92 (AgrEvo), where the EPO’s Board of Appeals held…
The UK Parliament closed down for business yesterday, preceding the general elections of 8 June 2017. It means parliamentary approval of legislation which is necessary for UK ratification of the Unified Patent Court Agreement will be delayed. Inevitably, this will lead to postponement of the start of the Unitary Patent system as well. After earlier…
The Unitary Patent system adds to territorial fragmentation of patent law in Europe, rather than consolidating it, by leaving aside non-participating EU Member States. Also, it is based on rules in the Brussels I bis Regulation (BR) and the Unifed Patent Court Agreement (UPCA) which are not consistent, according to Dr. Michael C.A. Kant, expert…
The sunrise session of day 2 was on second medical use claims and the hot European topic of plausibility. Floyd LJ began with a potted history and explained that whereas plausibility can be raised in different invalidity contexts the overall point is that the scope of the claim needs to be justified by the technical…
Activities of Patent assertion entities (PAEs) in Europe are increasing dramatically and are encouraged by the Rules of Procedure of the upcoming Unified Patent Court, especially the possibility to obtain an EU wide injunction. This is argued by Intellectual Property 2 Innovate (IP2I), a coalition made up with nine companies ‘that create innovative products and…
In Germany, the winning party is able to recover a significant amount of its costs from the losing party. This cost reimbursement, which is based on a statutory fee schedule, depends on the value of the case. The amount of recoverable fees can be quite significant; the maximum in infringement proceedings would be around slightly…
The Fordham IP Conference in New York is celebrating its 25th anniversary this year. As the conference heads into its second quarter-century, the programme and faculty are as impressive as ever. It remains a magnet for key opinion leaders from all areas of intellectual property. Whilst the rain poured down across Manhattan, the conference began…
On 17 June 2016 the Maritime and Commercial court declared AstraZeneca’s patent DK/EP 0 907 364 invalid, rendering the preliminary injunctions granted against Teva and a number of other competitors void as a result. The issue of damages was set a side for separate adjudication and the Maritime and Commercial court delivered its judgement on…
UK prime minister Theresa May’s decision to call early general elections for 8 June 2017 could spell trouble for the Unitary Patent system, as it may delay the UK’s ratification of the Unified Patent Court Agreement. Nobody said the creation of a new patent system covering all EU member states was going to be easy….
Given the furore surrounding Birss J’s decision on the non-technical issues in Unwired Planet v Huawei earlier this month, which included the first determination of FRAND terms by an English Court (reported on by my colleague Rachael here), it would have been easy to miss the first appellate Court judgment on the related technical issues…
